Biofrontera Nears Potential Breakthrough with FDA Decision
AI Prediction of Biofrontera (BFRI)
Biofrontera is poised for significant milestones in 2026, with potential FDA approval and expanded commercial endeavors likely to drive stock performance.
Biofrontera Inc., a small-cap biopharmaceutical company, specializes in dermatological conditions treated with photodynamic therapy (PDT). The company already markets Ameluz, a topical gel for actinic keratosis, and the RhodoLED lamp. Key catalysts include an upcoming PDUFA date in September 2026 for sBCC and potential label expansions. These developments could significantly increase the market size and enhance commercial credibility, especially given the recent positive Phase 3 results and ongoing commercialization efforts in the U.S. market. Investors should monitor these regulatory milestones closely as they are likely to impact the stock's price significantly.
BFRI Report Information
Prediction Date2026-03-27
Close @ Prediction$0.81
Mkt Cap7m
IPO DateN/a
AI-derived Information
Recent News for BFRI
- Aug 14, 8:30 am — Biofrontera Inc. Q2 2026 Earnings Call Summary (Moby)
- Aug 13, 7:03 pm — Biofrontera Inc (BFRI) (Q2 2026) Earnings Call Highlights: Strong Ameluz Growth Drives Revenue ... (GuruFocus.com)
- Aug 13, 4:41 pm — BFRI SEC filing points to financing activity (ScanScor Filing Bot)
- Aug 13, 9:00 am — BFRI SEC filing points to financing activity (ScanScor Filing Bot)
- Aug 13, 8:51 am — Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth (GlobeNewswire RSS)
- Aug 12, 9:35 am — Earnings To Watch: Biofrontera Inc (BFRI) Q2 2026 -- GF Value Sees 51% Downside (GuruFocus.com)
- Aug 5, 4:15 pm — Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026 (GlobeNewswire RSS)
- Jun 17, 4:05 pm — BFRI SEC filing points to financing activity (ScanScor Filing Bot)
- May 21, 9:15 am — Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026 (GlobeNewswire RSS)
- May 19, 9:34 am — StubHub, Jazz Pharmaceuticals upgraded: Wall Street's top analyst calls (The Fly)
- May 14, 7:04 pm — Biofrontera Inc (BFRI) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic ... (GuruFocus.com)
- Mar 20, 9:01 pm — Biofrontera Inc (BFRI) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ... (GuruFocus.com)
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.
Subscribe
Login
Please login to comment
0 Comments
Oldest
